The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumab
Abstract
During the last 5 years, numerous publications have demonstrated the potential value of chemotherapy in downstaging patients with hepatic metastasis from colorectal cancer (CRC). Improvements in fluorouracil (FU) -based chemotherapy by the addition of irinotecan or oxaliplatin has led to resectability rates of 12% to 22% in those patients who were initially deemed unresectable. Patients who subsequently undergo resection can achieve a respectable 5-year survival rate (30% to 35%). The addition of bevacizumab, a monoclonal antibody to vascular endothelial growth factor A (VEGF-A), and other targeted therapies (such as cetuximab) to cytotoxic chemotherapy improves response rates further, and it certainly is possible that this could increase the rate of resection. However, this brings one to question the effect of targeted therapies, with or without cytotoxic chemotherapy, on wound healing and hepatic regeneration in patients who undergo liver resection after neoadjuvant therapy. Well-designed preclinical studies have demonstrated that inhibition of angiogenesis can inhibit wound healing. Interestingly, there are no published studies examining the effect of anti-VEGF therapy on liver regeneration. One of the reasons for this lack of data is the fact that studies on liver regeneration in murine models cannot be done with bevacizumab because this antibody specifically recognizes the human form of VEGF and not murine VEGF. It must be remembered that VEGF-A binds to both VEGF receptor 2 (VEGFR2) and VEGFR1, which mediate distinct functions on endothelial cells and other cell types. Bevacizumab, therefore, theoretically can inhibit the activity of both receptors that likely play a role in liver regeneration. In the pivotal phase III clinical trial comparing bolus FU/leucovorin/irinotecan with or without bevacizumab as first-line therapy of advanced CRC, patients who underwent surgery while receiving bevacizumab had a slightly higher (yet not statistically significant) complication rate than those receiving chemotherapy alone (six of 39 v one of 25). A subsequent analysis of pooled data confirmed the increased incidence of complications in patients undergoing surgery while receiving bevacizumab-containing regimens for metastatic CRC. Although these numbers are small, one must recognize the fact that anti-VEGF therapy does inhibit wound healing. Potential inhibition of normal hepatic regeneration becomes even more important when patients are being considered for hepatic resection after downstaging while receiving, or shortly after being treated with bevacizumab-containing regimens. VEGF plays a critical role in liver regeneration after partial hepatectomy or chemical injury. VEGF not only regulates angiogenesis in the regenerating liver, but also mediates a paracrine pathway by which other cytokines can be upregulated in liver sinusoidal endothelial cells. For example, activation of VEGFR1 on liver sinusoidal endothelial cells leads to induction of hepatocyte growth factor that, in turn, mediates liver repair. Interestingly, in regenerating livers in animals with hepatic steatosis, the angiogenic response is impaired. Cytotoxic chemotherapy drugs can induce hepatic steatosis. In patients with CRC metastases who undergo downstaging of their disease by chemotherapy, hepatic steatosis can be present in up to 45% of patients. Therefore, in patients who undergo hepatic resection after treatment with bevacizumab-containing regimens, one must be cognizant of the fact that hepatic regeneration may be impaired due to several mechanisms. Regardless of the mechanism of impaired hepatic regeneration, it is critical to determine the appropriate timing of surgery in patients presenting with CRC metastases who are being considered for liver resection after being treated with bevacizumab-containing chemotherapeutic regimens. In contrast to standard chemotherapeutic agents, the half-life of bevacizumab is relatively long. In pharmacokinetic studies, the mean half-life of bevacizumab is approximately 20 days, but the range varies between 11 and 50 days. Males and patients with large tumor burden seem to JOURNAL OF CLINICAL ONCOLOGY COMMENTS AND CONTROVERSIES VOLUME 23 NUMBER 22 AUGUST 1 2005
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Cited by
Strategies for Safer Liver Surgery and Partial Liver Transplantation
Clavien, P.-A., Petrowsky, H., DeOliveira, M. L., & Graf, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra065156 · Cited by 1,022
Gruenberger, B., Tamandl, D., Schueller, J., Scheithauer, W., Zielinski, C., Herbst, F., & Gruenberger, T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.7679 · Cited by 423
Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M. B., Eng, C., Chang, D. Z., Curley, S. A., Abdalla, E. K., Ellis, L. M., et al. (2007) · Cancer · doi:10.1002/cncr.23099 · Cited by 375
Self-citationTESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
MANZANO, R. P. A., PEYMAN, G. A., KHAN, P., & KIVILCIM, M. (2006) · Retina · doi:10.1097/00006982-200603000-00001 · Cited by 305
Nordlinger, B., Van Cutsem, E., Rougier, P., Köhne, C.-H., Ychou, M., Sobrero, A., Adam, R., Arvidsson, D., Carrato, A., Georgoulias, V., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.07.017 · Cited by 272
Metadata
- Authors
- Ellis, L. M., Curley, S. A., & Grothey, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-01
- Volume
- 23
- Issue
- 22
- Pages
- 4853-4855
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097881540
- Cited by
- 163
- References
- 3
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumab. https://app.cochat.ai/papers/10.1200/jco.2005.23.754
- The paper
- Ellis, L. M., Curley, S. A., & Grothey, A. (2005). Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumab. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.23.754
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.